Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.

The user started using 0.5mg Dutasteride, switched to 10mg oral Minoxidil, and began micro-needling in February 2026, noticing slow but steady hair growth. Other users suggest using lower doses of Minoxidil and commend the visible progress.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

The user started finasteride and minoxidil 4 months ago and experienced shedding, which stopped but resumed after starting creatine. Other users suggest the shedding is likely from the treatment, not creatine, as creatine is not linked to hair loss.

A 24-year-old reported new hair growth on temples after 3.5 months of using topical minoxidil without shedding. They plan to add finasteride to maintain progress, as minoxidil alone may not be enough long-term.

There is no permanent cure for hair loss; treatments like finasteride, minoxidil, and hair transplants require ongoing use and are not universally effective. Genetic complexity and financial incentives for ongoing treatments hinder the development of a definitive cure.

Dutasteride is often blamed for worsening hair loss, but initial shedding may lead to improvement, requiring patience. Some users find success with dutasteride, finasteride, and minoxidil, while others experience side effects or no improvement.

Creatine is unlikely to cause hair loss as it does not raise DHT levels. Hair loss is more likely due to genetics, medications, or lifestyle changes.

Finasteride may take over two years to show results and can cause side effects like sexual dysfunction and emotional changes. Alternatives such as dutasteride and minoxidil are discussed, with varying effectiveness and side effects.

Participants want to maintain hair until at least age 30, using treatments like finasteride, dutasteride, and minoxidil. Hair loss remains a concern, with some considering hair transplants.

A 24-year-old shared his 12-month hair loss progress, using 1mg oral finasteride daily, Minoxidil spray twice daily, weekly derma stamping, daily Biotin, Saw Palmetto Shampoo, and occasional Ketoconazole shampoo. He experienced minimal side effects and significant hair density improvement, no longer needing a hat.

A user shared their one-year progress using finasteride 1mg three times a week, starting at age 25, with noticeable regrowth after three months and no side effects. Other users discussed their experiences with finasteride, minoxidil, microneedling, and dutasteride, noting varying results and side effects.

The user is experiencing slow but solid hair regrowth using topical finasteride, oral minoxidil, keto shampoo, microneedling, RU58841, and rosemary oil. Another user suggests being grateful for the dense coverage.

A user is seeking a titanium dioxide-free finasteride pill due to health concerns. They have not found a suitable supplier yet.

The conversation discusses the effectiveness of Dutasteride (DUT) and Finasteride (FIN) for hair loss. Users share varied experiences, with some finding DUT more effective and others experiencing side effects or no change, highlighting that individual responses can vary.

The post argues for teenage use of finasteride to prevent hair loss, citing minimal side effects and personal success. Replies criticize the advice, highlighting potential developmental risks and questioning the safety of finasteride for teenagers.

Rice water was used as a hair treatment and showed noticeable results in a week, more than finasteride used for seven months. The user plans to continue using rice water and might stop finasteride, while still using ketoconazole for dandruff.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

Oral supplementation of Nicotinamide Mononucleotide (NMN) improves hair quality and appearance in middle-aged women. However, it may reduce total hair density, possibly due to seasonal shedding.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.